Admedus (ASX:AHZ) has appointed Simon Buckingham to its board of directors as a non-executive director to replace outgoing Michael Bennett.
Buckingham has more than 25 years’ experience in the global pharmaceutical industry across a range of functions and a variety of therapeutic areas.
He is currently a senior global advisor to Actelion, one of the world’s leading biopharmaceutical companies, and is a director of Actelion Australia.
Buckingham is currently a non-executive director of Pharmaxis (ASX:PXS), a pharmaceutical research company with a portfolio including two respiratory products approved in various world markets and a research pipeline focused on areas of high unmet clinical need in inflammatory and fibrotic diseases.
He also sits on the boards of Creso Pharma (ASX:CPH) and Vaxxilon AG.
Wayne Paterson, chairman, commented: “Simon Buckingham brings to Admedus an extremely impressive depth of experience and a full spectrum of the most relevant qualifications.
“The board welcomes him to Admedus and looks forward to his insight and contribution as we continue the Company’s progress with growth and expansion.”